redlamp 6: entecavir vs. lamivudine in preventing hepatitis b reactivation in untreated dlbcl
Published 9 years ago • 2.5K plays • Length 4:19Download video MP4
Download video MP3
Similar videos
-
4:32
redlamp 5: rituximab vs. watch & wait approach in patients with advanced follicular lymphoma
-
6:11
redlamp 9: prognostic factors for clinical outcomes in patients with plasmablastic lymphoma
-
4:49
redlamp 11: does a family history of lymphoma increase my risk?
-
6:11
redlamp 3: bortezomib-based therapy for newly diagnosed mantle cell lymphoma
-
2:15
vipor: a multi-targeted therapy for the treatment of r/r dlbcl
-
0:53
arc-8: ab680 zimberelimab for first-line mpdac
-
1:04
bispecific afm13 plus pembro for r/r hodgkin lymphoma
-
1:15
personalized medicine for dlbcl
-
2:18
lintuzumab-ac225 combined with venetoclax for r/r aml: early results
-
1:21
ruxolitinib plus venetoclax in heavily pretreated patients with r/r aml
-
3:23
dreamm-6: belamaf-based combination therapy in r/r mm
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:22
select-aml-1: tamibarotene with venetoclax and azacitidine in patients with rara-positive aml
-
1:38
the safety and efficacy of belantamab mafodotin in r/r multiple myeloma in the real world
-
3:53
investigating the combination of pivekimab sunirine, azacitidine & venetoclax in r/r aml
-
2:03
the use of venetoclax in r/r al amyloidosis
-
4:18
immunotherapy in refractory dlbcl
-
1:54
the important role of bispecific antibodies in the future treatment of r/r dlbcl